Highlights
Persistent symptom burden in acromegaly often continues despite biochemical remission, particularly fatigue, joint pain, sleep disturbance, body-image concerns, and impaired physical functioning.
Patient-reported outcome measures consistently show discordance between hormone control and lived experience, indicating that insulin-like growth factor 1 and growth hormone values alone do not capture disease impact.
Treatment burden is substantial and includes injection inconvenience, gastrointestinal adverse effects, breakthrough symptoms, frequent surveillance, lost work productivity, and financial stress.
Patient-centered acromegaly care increasingly requires standardized patient-reported outcome assessment, multidisciplinary management, and shared decision-making around both efficacy and burden of therapy.
Background and Clinical Context
Acromegaly is a chronic disorder caused in most cases by growth hormone-secreting pituitary adenomas, leading to excess growth hormone and hepatic overproduction of insulin-like growth factor 1 (IGF-1). The disease evolves insidiously. By the time of diagnosis, patients often have accumulated irreversible structural and functional morbidity involving the musculoskeletal, cardiovascular, respiratory, metabolic, and neuropsychological systems. Surgery, medical therapy, and radiotherapy can improve biochemical control and reduce long-term complications, but remission does not necessarily restore normal health status.
The review by Geer and Sisco in The Journal of Clinical Endocrinology and Metabolism brings a clinically important point into focus: acromegaly should not be judged solely by laboratory normalization. The patient experience includes persistent pain, fatigue, soft tissue changes, altered appearance, mood symptoms, social impairment, and treatment fatigue. These issues matter because they influence adherence, daily function, employment, and satisfaction with care. For clinicians, the message is straightforward: disease activity and disease burden are overlapping but nonidentical constructs.
Review Scope and Evidence Base
This article is a narrative review synthesizing evidence from clinical trials, registry analyses, longitudinal cohort studies, cross-sectional observational work, and patient-reported outcome research. Rather than testing a single intervention, it evaluates how acromegaly and its treatments affect patient experience across several domains: physical symptoms, health-related quality of life (HRQoL), emotional well-being, interpersonal relationships, work productivity, and financial burden.
The review also assesses commonly used acromegaly-specific and treatment-specific patient-reported outcome instruments, including the Acromegaly Quality of Life Questionnaire (AcroQoL), Patient-Assessed Acromegaly Symptom Questionnaire (PASQ), Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ), and the Acromegaly Symptom Diary (ASD). This focus is especially relevant because patient-reported outcomes are increasingly recognized by regulators, guideline groups, and endocrine specialists as necessary endpoints alongside biochemical and radiographic markers.
Core Findings: The Burden of Symptoms Remains High
Physical symptoms often persist after biochemical control
The review emphasizes that many patients continue to experience clinically significant symptoms even after achieving accepted biochemical targets. Fatigue emerges as one of the most pervasive and functionally limiting complaints. Musculoskeletal pain, arthropathy, headache, sweating, soft tissue swelling, and sleep-related problems are also common. In practice, these symptoms may reflect a combination of persistent disease activity, irreversible tissue changes from prior hormone excess, comorbid sleep apnea, degenerative joint disease, and treatment effects.
Arthropathy is especially important because it contributes disproportionately to chronic pain and disability. Unlike some soft tissue manifestations, joint damage may not fully reverse with treatment. This explains why a patient with normalized IGF-1 may still report poor mobility, reduced exercise tolerance, and diminished quality of life. The review highlights this clinical disconnect as a recurring pattern across cohorts.
Appearance-related and body-image concerns are clinically meaningful
Acromegaly visibly alters the face, extremities, dentition, and body habitus. Even when soft tissue swelling improves, some changes persist. Patients may experience embarrassment, altered self-perception, social withdrawal, and strain in intimate relationships. These effects are often underrecognized in routine endocrine practice because they may not be volunteered unless specifically asked. Yet body-image disturbance can be a major mediator of psychological distress and reduced HRQoL.
Sleep disturbance compounds morbidity
Sleep impairment in acromegaly is multifactorial. Obstructive sleep apnea, residual craniofacial and upper airway changes, pain, and mood disorders all contribute. Poor sleep, in turn, worsens fatigue, concentration, work function, and emotional resilience. The review appropriately frames sleep burden not as an isolated symptom but as a cross-cutting determinant of overall well-being.
Health-Related Quality of Life: Persistent Impairment Across Domains
One of the strongest conclusions of the review is that HRQoL remains impaired in many patients despite therapeutic advances. Deficits extend across physical, psychological, and social domains. This finding is consistent with prior literature showing lower HRQoL scores in acromegaly compared with population norms and, in some studies, compared with other chronic endocrine conditions.
The physical domain is affected by pain, limited mobility, fatigue, and sleep disruption. The psychological domain is shaped by depression, anxiety, self-consciousness, and fear of recurrence or disease worsening. The social domain includes difficulties with intimacy, social participation, and role performance at home and work. Importantly, these dimensions are interdependent. A patient with chronic pain may become less active, sleep poorly, and then develop low mood and reduced occupational functioning. The review therefore supports integrated rather than compartmentalized management.
Depression and anxiety are common but may be undertreated
Mood symptoms affect a substantial proportion of patients with acromegaly. Some of this burden may be reactive to chronic illness and altered appearance, while some may relate to neurobiological effects of prolonged hormone excess, comorbid medical disease, or treatment strain. Regardless of mechanism, depression and anxiety worsen adherence, amplify symptom perception, and reduce life satisfaction. The review argues implicitly for more systematic mental health screening in endocrine follow-up, especially in patients whose laboratory values appear controlled but who continue to report poor functioning.
Why Biochemical Remission Does Not Equal Recovery
A central scientific and clinical insight from the review is the repeated discordance between biochemical control and patient-reported outcomes. This phenomenon is not surprising when considered pathophysiologically. Growth hormone excess causes structural changes, including osteoarthropathy, spinal disease, craniofacial remodeling, and soft tissue enlargement, some of which may be only partially reversible. Comorbid conditions such as diabetes, hypertension, cardiomyopathy, hypopituitarism, and sleep apnea may persist after hormone normalization. In addition, living for years with a disfiguring and chronic disease can leave durable psychological and social effects.
Therefore, biochemical remission should be seen as necessary but not sufficient. For clinicians, this has two practical implications. First, persistent symptoms should not be dismissed simply because IGF-1 is normal. Second, treatment success should be defined using a broader framework that includes symptom control, function, treatment satisfaction, and reduction of daily burden.
Treatment Burden as a Distinct Clinical Problem
Injections, timing, and breakthrough symptoms
Long-acting injectable somatostatin receptor ligands remain a cornerstone of medical therapy for many patients. However, the review details the burden associated with repeated clinic visits or self-administration, injection-site discomfort, scheduling constraints, and cyclical breakthrough symptoms near the end of a dosing interval. Even effective therapy can feel intrusive when it repeatedly disrupts routine life or when symptom relief fluctuates between doses.
This aspect of treatment burden is clinically important because it affects both satisfaction and adherence. A regimen that controls IGF-1 but leaves the patient with predictable end-of-dose deterioration may be judged inadequate from the patient perspective, even if the clinician views the same regimen as successful.
Adverse effects and surveillance demands
Gastrointestinal effects from somatostatin receptor ligands, concerns about glucose intolerance, and the need for regular laboratory and imaging surveillance further add to disease workload. For patients receiving pegvisomant, injection frequency and monitoring requirements may be significant. For those previously treated with radiotherapy, long-term surveillance for delayed hypopituitarism and other complications adds another layer of chronic management. The cumulative effect is a sustained administrative and psychological burden that extends beyond direct symptom control.
Financial toxicity and work productivity loss
The review also underscores the economic dimension of acromegaly. This includes direct treatment costs, travel and time for appointments, insurance complexity, and indirect losses from absenteeism, presenteeism, reduced work capacity, or early retirement. These burdens are especially relevant for working-age adults who may appear outwardly stable yet struggle with pain, fatigue, and treatment schedules. For health systems and employers, acromegaly therefore represents not only a rare endocrine disease but also a chronic condition with meaningful productivity consequences.
Patient-Reported Outcome Instruments: What They Add
AcroQoL
The Acromegaly Quality of Life Questionnaire is among the most widely used disease-specific instruments. It captures physical and psychological dimensions, including appearance and personal relations. Its value lies in detecting persistent impairment that routine endocrine visits may miss.
PASQ
The Patient-Assessed Acromegaly Symptom Questionnaire focuses on key symptoms such as headache, perspiration, fatigue, soft tissue swelling, and joint pain. It is useful for tracking symptom trends over time and for identifying residual disease burden even during biochemical control.
Acro-TSQ and ASD
The Acromegaly Treatment Satisfaction Questionnaire and Acromegaly Symptom Diary extend the assessment from symptoms alone to treatment experience, convenience, emotional reactions, and day-to-day symptom variability. These tools are especially relevant when comparing formulations, delivery methods, or dosing intervals.
The review highlights an important methodological gap: despite increasing use of these instruments, standardized implementation and validated minimal important difference thresholds remain incomplete. Without clear thresholds for clinically meaningful change, it is harder to interpret trial results, compare studies, or embed PROs into routine care pathways. This is a major agenda item for future research.
Therapeutic Advances and Their Potential Impact on Patient Experience
New oral therapies and longer-acting formulations may reduce treatment burden, particularly by minimizing injections and simplifying administration. The review notes that these approaches are promising from a patient-centered perspective, but comparative PRO data remain limited. This is a key limitation in the current evidence base. Too often, new therapies are evaluated mainly on biochemical endpoints, while convenience, day-to-day symptom control, treatment satisfaction, and work-function outcomes receive less rigorous attention.
For clinicians choosing between surgery, injectable medical therapy, oral options, combination regimens, or radiotherapy, the optimal strategy may differ depending on patient priorities. A patient with severe injection fatigue may value convenience highly. Another may prioritize maximal biochemical control despite more intensive monitoring. Shared decision-making therefore becomes central, not optional.
Clinical Interpretation and Practice Implications
The review supports a shift from hormone-centric management to genuinely patient-centered longitudinal care. Several practical measures follow from this evidence.
First, PRO assessment should become routine in specialty care, ideally using validated acromegaly-specific instruments rather than generic symptom checklists alone. Second, persistent pain, sleep dysfunction, depression, sexual and relational concerns, and occupational difficulties should trigger targeted intervention rather than reassurance alone. Third, multidisciplinary care is essential. Endocrinologists, pituitary neurosurgeons, sleep specialists, psychologists or psychiatrists, pain and rehabilitation teams, and specialized endocrine nurses all have a role in reducing the lived burden of disease.
Fourth, treatment burden should be discussed explicitly during regimen selection. Questions about route of administration, symptom control across the dosing interval, travel, cost, time away from work, and patient preference should be treated as legitimate determinants of therapeutic choice. Fifth, follow-up should distinguish irreversible sequelae from active disease, because the management strategies differ. An elevated symptom burden in a biochemically controlled patient may reflect osteoarthritis, untreated sleep apnea, hypopituitarism, or depression rather than uncontrolled acromegaly itself.
Limitations of the Evidence
As a review of heterogeneous studies, the strength of inference is constrained by variable study design, sample size, and PRO methodology. Rare disease populations are often small, and cross-sectional designs make it difficult to disentangle the effects of current disease activity from accumulated irreversible morbidity. Selection bias may also affect registry and specialty-center cohorts. In addition, differences in biochemical targets, remission definitions, prior treatments, and comorbidity burden complicate direct comparisons across studies.
Another limitation is that PRO instruments, while valuable, do not yet have universally established implementation frameworks in routine endocrine practice. Broader use will require consensus around timing, threshold interpretation, and response pathways when clinically meaningful deterioration is detected.
Expert Commentary
The larger significance of this review is that it aligns acromegaly with a broader movement in chronic disease management: outcomes that matter to patients must be measured directly. In endocrine practice, there has historically been heavy reliance on hormone normalization as the main indicator of success. This review argues convincingly that such an approach is incomplete. It also highlights a translational opportunity. If future trials routinely integrate robust PRO endpoints, clinicians will be better able to match therapies not only to tumor and biochemical phenotype, but also to patient lifestyle, preferences, and functional goals.
This perspective is also consistent with contemporary pituitary guidance, which increasingly recognizes quality of life, comorbidity management, and long-term surveillance as core components of care. The next step is operational: integrating these principles into clinic workflows in a way that is standardized, efficient, and actionable.
Conclusion
The review by Geer and Sisco makes a clinically important argument: acromegaly remains a high-burden chronic disease even in the era of improved biochemical control. Fatigue, pain, arthropathy, sleep disturbance, appearance-related distress, depression, anxiety, treatment inconvenience, and financial strain continue to shape patient lives long after hormone values improve. Patient-reported outcomes expose a persistent gap between biochemical remission and real recovery.
For modern acromegaly care, the implication is clear. Success should no longer be defined by IGF-1 and growth hormone alone. It should include symptom relief, quality of life, treatment satisfaction, preserved work and social function, and a care plan that patients can realistically sustain. Closing that gap will require routine PRO use, multidisciplinary management, better comparative data on treatment burden, and more deliberate shared decision-making.
Funding and Trial Registration
The cited publication is a review article and does not represent a single registered clinical trial. Specific funding information should be verified from the full text of the article: Geer EB, Sisco J. The acromegaly patient experience: burden of treatment and quality of life. The Journal of Clinical Endocrinology and Metabolism. 2026-Jun-04;111(Supplement_1):S123-S145. PMID: 42014048.
References
Geer EB, Sisco J. The acromegaly patient experience: burden of treatment and quality of life. The Journal of Clinical Endocrinology and Metabolism. 2026;111(Supplement_1):S123-S145. PMID: 42014048.
Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology. 2018;14(9):552-561.
Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2014;99(11):3933-3951.
Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (AcroQoL), a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology. 2002;57(2):251-258.
van der Lely AJ, Gomez R, Pleil A, et al. Development of ACRODAT and patient-centered tools in acromegaly management contributed to recognition of discordance between biochemical control and disease burden; readers should consult original PRO validation literature for instrument-specific methodology.